FDA OKs CardioDynamics third-generation heart monitor:
This article was originally published in Clinica
The US FDA has given CardioDynamics 510(k) clearance to market its third-generation impedance cardiography (ICG)-based product for monitoring the heart in a noninvasive fashion. The BioZ Dx system represents the first phase of a co-development partnership between the San Diego, California company and Philips Medical Systems; following its immediate release into the market, BioZ Dx will be upgradeable to include Philips' 12-lead ECG technology in late 2005.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.